People channel feed

Ex-Mod­er­na CFO Lorence Kim joins a new class of ven­ture part­ners jump­ing on board Third Rock

We now know where Lorence Kim will play out the next chapter of his life sciences career.

Back in May, Moderna — one of the top players in the race to develop a Covid-19 vaccine — announced that their CFO was headed to the exit in August, setting up a switch in the executive suite. Tuesday morning Third Rock announced via Twitter that Kim is hopping on board the high-profile biotech VC as a new venture partner.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Fol­low­ing job cuts and R&D re­struc­tur­ing, mi­cro­cap mi­croR­NA play­er mi­Ra­gen brings in new CEO to right the ship

Four years after riding the shell of a struggling microcap biotech to Nasdaq with $40 million in cash, microRNA player miRagen Therapeutics is facing a reckoning of its own.

After the market close Thursday, miRagen disclosed a flurry of changes at the company: CEO William Marshall has resigned, leaving COO Lee Rauch in charge as the new chief to oversee a “review of strategic alternatives” — often a sign that the board is eager for a sale, although in-licensing and other deals are also on the table.

Peter Emtage (file photo)

Scoop: Gilead’s CAR-T play­er Kite waves good­bye to re­search chief Pe­ter Em­tage as an­oth­er top ex­ec hits the ex­it

Endpoints News has learned that Peter Emtage, the head of research at Gilead CAR-T subsidiary Kite, is leaving the company at the end of this month.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Rob Neville (L) and Taneli Jouhikainen

Savara's long-reign­ing duo both re­sign in the wake of CF bust

As Savara’s cystic fibrosis development program comes to an end, so will the CEO Rob Neville’s 12-year reign at the company.

Following him out the door is his co-founder Taneli Jouhikainen, Savara’s president and chief business officer, who’s resigning to “pursue other opportunities.” Matthew Pauls, the former chief of Strongbridge and a member of the board, is stepping in as chairman and interim CEO.

Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images)

$1.6 bil­lion liq­uid biop­sy play­er Grail files IPO, re­veal­ing 2021 com­mer­cial plans and a Mi­das-sized $65M pay pack­age for Hans Bish­op

The hunt for the Grail just got a lot easier. In fact, in a few weeks you’ll likely be able to pick up a portion of it on Robin Hood, no coconut horses required.

Grail, the monstrously backed liquid biopsy biotech, has filed for an IPO. No pricing details have been disclosed, but if history is any indicator, the company will have a chance to cap 6 months of booming pandemic-era offerings the way the billion-dollar Dark Knight films would cap the summer blockbuster in their heyday. CEO Hans Bishop has penciled in $100 million for the raise, but that figure has become a standard placeholder until biotechs can gauge exactly how much they can raise.

Andrew Hirsch, C4 Therapeutics CEO (Endpoints file photo; Christine Hochkeppel)

Long­time biotech vet An­drew Hirsch is tak­ing the top job at C4 — and he clear­ly has some big plans

Four years after Andrew Hirsch tied the last loose end on Bind’s bankruptcy package and shipped to Agios as its CFO, he is back at the helm.

After the market closed on Tuesday, we learned that Hirsch is taking the CEO post at C4 Therapeutics, which is making every effort necessary to do the window dressing for a major league biotech IPO. He’s taking the place of Andrew Phillips, who hit the exit 2 years after he was promoted from CSO to CEO.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Fouad Namouni, Blueprint Medicines president of R&D (BMS)

An­oth­er Big Phar­ma 'lif­er' in the top ranks of R&D is start­ing a new chap­ter in biotech

Fouad Namouni, a storied research exec who went from project leader on Opdivo and Yervoy to the top of the oncology research group at Bristol Myers Squibb, is joining the migration to biotech, picking up a new hat as president of R&D at Blueprint Medicines.

Once again, he’s headed into a toe-to-toe showdown with a rival pharma organization.

Namouni will likely be coming on board just one step ahead of an approval for pralsetinib, Blueprint’s RET rival to Eli Lilly’s Retevmo, which got out in front with a May approval. Ironically, Lilly’s deal to buy into RET with its acquisition of Loxo also brought Josh Bilenker and his crew to the pharma giant, marking a rare career trajectory from a biotech into pharma, which has been bleeding talent for years now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Stephen Hahn, FDA commissioner (Alex Brandon/AP Images)

FDA com­mis­sion­er Hahn ousts agency’s new chief spokesper­son as plas­ma con­tro­ver­sy con­tin­ues to smol­der

FDA commissioner Stephen Hahn capped a week of controversy over a fiasco revolving around his misleading comments on a Covid-19 treatment by ousting the agency’s newly-hired chief spokesperson, Emily Miller.

Miller had worked at the right-wing cable news network One America News — a favorite of President Trump’s — as well as for the campaign of Senator Ted Cruz before she was placed at the FDA just 11 days ago, according to the New York Times, which broke the story. Her appointment raised eyebrows at an agency that has long hired civil servants for such positions and worked to maintain its independence from political winds.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

Shahram Seyedin-Noor, Civilization Ventures

A small VC group ex­pands its hunt for in­spired biotech founders in need of seed cash

Civilization Ventures, a California-based VC fund that successfully bet on biotechs Rocket Pharmaceuticals and Singular Bio a few years ago, is bringing forth its next round of investments.

Founded by entrepreneur Shahram Seyedin-Noor, the company has closed a $35 million fundraise and announced Tuesday morning it plans to invest in three areas: diagnostics, synthetic biology and AI-related digital health. The new life sciences capital comes three years after Civilization’s first fund, an $8 million pool that saw Rocket go public through reverse merger and Singular be acquired by medical-genetics company Invitae.

Troy Wil­son re­cruits As­traZeneca vet to steer Ku­ra's late-stage piv­ot

Seven months after Kura Oncology bid farewell with co-founder and chief medical officer Antonio Gualberto, the biotech has found his successor from the ranks of Big Pharma alumni.

With Phase II data in hand for the lead drug, tipifarnib, and a second program almost ready for the clinic, the biotech was looking for someone well versed in targeted therapy development and experienced with regulators, CEO Troy Wilson told Endpoints News.